miR-448通过抑制上皮间质转化抑制肺癌细胞增殖和运动能力

探讨mi R-448对肺癌细胞增殖和运动的影响及其分子机制。采用实时荧光定量PCR(polymerase chain reaction)检测原发肺癌组织和癌旁正常组织mi R-448表达水平。转染mi R-448 mimic和inhibitor至肺癌A549细胞系,通过MTT(3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazoliumbromide)、平板克隆形成和Transwell实验观察mi R-448表达对A549增殖和运动能力的影响;利用Western blot检测EMT(epithelial-mesenchymal transition)标志物蛋白表达水平,通过实时荧光定量PCR检测EMT相关转录因子m RNA表达水平。实时荧光定量PCR显示较癌旁正常组织相比,mi R-448在原发肺癌组织中表达降低。MTT和平板克隆形成实验显示,过表达mi R-448抑制A549细胞增殖和运动能力;降表达mi R-448增强A549细胞增殖和运动能力。Western blot显示降表达mi R-448能下调上皮标志物E-cadherin,上调间质标志物Vimentin表达水平。实时荧光定量PCR显示降表达mi R-448能上调EMT相关转录因子Twist1和ZEB1 m RNA表达水平。mi R-448可通过抑制EMT抑制肺癌进展。     

miR-106b-93-25簇对子宫内膜癌细胞的调控作用研究

目的:检测mi R-106b-93-25基因簇对子宫内膜癌细胞增殖及凋亡的影响,并探讨其机制。方法:q RT-PCR检测临床子宫内膜癌标本及癌旁正常组织中mi R-106b、mi R-93和mi R-25及其宿主基因MCM7的表达情况。将micro RNA及其拮抗剂转染ECC-1细胞后,MTT实验检测ECC-1细胞增殖情况,流式细胞术检测ECC-1细胞周期及细胞凋亡情况。荧光素酶报告系统验证mi R-106b和mi R-25分别直接调控p21和Bim。结果:临床标本子宫内膜癌组织与癌旁正常组织相比mi R-106b-93-25簇及其宿主基因MCM7的表达明显增高。mi R-106b-93-25簇能够促进ECC-1细胞增殖,减少凋亡。转染mi R-106b和mi R-93的细胞出现明显的S期阻滞,过表达mi R-25的细胞凋亡明显减少。mi R-106b-93-25簇通过抑制靶基因p21和Bim的表达,引起促增殖、抗凋亡作用。结论:mi R-106b-93-25簇能够促进子宫内膜癌细胞增殖,抑制凋亡,并使细胞发生S期阻滞。mi R-106b-93-25簇在子宫内膜癌的发生与发展中具有重要的作用。     

miR-199a-3p负调控CBX7影响肺癌细胞NCI-H460的生物学行为研究

目的:探讨mi R-199a-3p负调控CBX7影响肺癌细胞NCI-H460的生物学行为。方法:qRT-PCR法检测并比较肺癌组织、癌旁正常组织、肺癌细胞、正常肺上皮细胞中的mi R-199a-3p m RNA相对表达量。比较远处转移肺癌组织、未转移肺癌组织中mi R-199a-3p m RNA相对表达量。qRT-PCR法、Western Blot法检测并比较肺癌组织、癌旁正常组织中的CBX7 m RNA及蛋白的表达水平。荧光素酶活性法检测mi R-199a-3p与靶基因CBX7的结合。比较mi R-199a-3p模拟物转染组与阴性对照组的肺癌细胞中的CBX7 m RNA相对表达量及CBX7蛋白表达水平。CCK8实验检测mi R-199a-3p对肺癌细胞增殖的促进作用。Tranwell实验检测mi R-199a-3p对肺癌细胞侵袭与迁移能力的影响。结果:肺癌组织中mi R-199a-3p明显高于癌旁正常组织,发生远处转移的肺癌组织中mi R-199a-3p m RNA的表达量明显高于未发生转移的肺癌组织,差异有统计学意义(P<0.001)。肺癌组织中CBX7m RNA、CBX7蛋白表达水平均明显低于癌旁正常组织,差异有统计学意义(P<0.001)。荧光素酶活性法证实mi R-199a-3p可与靶基因CBX7结合抑制CBX7的表达。肺癌细胞中mi R-199a-3p m RNA的相对表达量明显高于正常肺上皮细胞,CBX7 m RNA相对表达量明显低于正常肺上皮细胞(P<0.05)。对于肺癌细胞,mi R-199a-3p模拟物转染组的CBX7 m RNA相对表达量及CBX7蛋白表达水平均明显低于阴性对照组(P<0.001)。CCK8实验证实mi R-199a-3p能够促进肺癌细胞的增殖,Tranwell实验证实mi R-199a-3p对肺癌细胞侵袭与迁移具有积极的促进作用。结论:mi R-199a-3p在肺癌的发生发展过程中发挥重要作用,能够通过抑制CBX7基因的表达,促进肺癌细胞的增殖、侵袭和转移。     

miR-183家族在肿瘤中作用机理的最新进展

micro RNA是真核生物中一类长约18~25个核苷酸的小分子非编码RNA,它们可以与m RNA的3′-UTR结合在转录后水平调控基因的表达。很多报道表明,mi RNA参与了肿瘤的发生发展调控。mi R-183家族的三个成员mi R-183、mi R-96和mi R-182都与肿瘤密切相关。研究发现,在前列腺癌、肺癌、结肠癌、乳腺癌等肿瘤中mi R-183家族表达异常,其机制是通过调控多种靶基因参与其中。本文综述了mi R-183家族在常见高发肿瘤中的研究现状。     

miR-489在肿瘤中作用的研究进展

mi RNA是一类长度约为22 nt的内源性小分子非编码RNA,几乎参与了机体生命活动的所有过程。近年来研究发现,多种肿瘤组织中mi R-489表达下调,其通过转录后抑制靶基因,如HER2、AKT3、SPIN1等的表达,参与肿瘤细胞的增殖、凋亡、侵袭和转移等多种病理过程,并与肿瘤的耐药及发生、发展密切相关。因此,了解mi R-489的表达、调控及其在肿瘤等疾病中的作用及机制,可为其进一步的临床应用奠定基础。本文就mi R-489与恶性肿瘤关系的研究进展进行综述。     

miR-181b-5p靶向调控Nr6a1抑制GC-1spg细胞的增殖与迁移

Micro RNA(mi RNA)是一段长约为22 nt的内源性非编码单链RNA,研究表明mi RNA对正常精子发生和雄性发育必不可少。为了探究mi R-181b-5p在雄性生殖细胞发育中的功能以及寻找其靶基因,首先采用流式细胞术、噻唑蓝检测以及划痕实验分析了mi R-181b-5p在小鼠GC-1spg精原细胞系中的生物学效应,随后利用Targetscan和GO数据库等生物信息学软件预测发现生殖核受体Nr6a1可能为其靶基因,进而通过双荧光素酶报告基因实验以及q PCR证实了mi R-181b-5p与Nr6a1的靶向识别关系,最后采用细胞功能回补实验明确了mi R-181b-5p通过靶向调控Nr6a1来抑制GC-1spg细胞的增殖和迁移。结果表明mi R-181b-5p通过其靶基因Nr6a1在精子发生中起到负调控的作用。     

精神分裂症相关miRNA筛选及miR-320a调控ITGB1机制研究

该文研究了精神分裂症(schizophrenia,Sz)患者血清中微小RNA(micro RNA,mi RNA)水平的变化,寻找其作用靶点并进行机制探索。通过mi RNA基因芯片分析4例患者、3例治愈患者及3例健康成年人血清中mi RNA表达的差异。使用荧光定量PCR对59例患者及60例对照血清进行验证。通过生物信息学分析寻找靶点,并在血清样本中检测;最后,在细胞水平进行mi RNA调控靶点的功能研究。芯片筛选发现,mi R-320a及mi R-320b在初诊患者中呈低表达,较治愈患者和健康人有显著性差异,并在59例初诊患者和60例健康人对照血清中得到验证。生物信息学分析发现,整合素β1(integrinβ1,ITGB1)可能是mi R-320a的作用靶点。ELISA结果发现,患者血清中ITGB1的浓度比健康成年人血清中的浓度呈显著升高。细胞水平的研究发现,mi R-320a模拟物可以下调ITGB1表达,mi R-320a抑制剂可以上调ITGB1表达。荧光素酶实验证实,mi R-320a可能通过结合于ITGB1m RNA 3′UTR的特异性位点,促使m RNA降解,从而调控其表达。结果表明,mi R-320a调控ITGB1的表达可能是Sz发病过程中的重要机制,这一发现有可能为Sz的早期诊断和治疗提供新的候选靶点。     

miR-345靶向调控 TGM1抑制膀胱癌的初步研究

目的:探讨mi R-345调控TGM1表达影响膀胱癌的分子生物学机制。方法:首先,采用RT-qPCR检测T24和RT4细胞中mi R-345、TGM1的表达;再采用mi RNA-NC、mi R-345 mimic、NC inhibitor、mi R-345 inhibitor、control si RNA、si TGM1和pc-DNA3.1/TGM1等转染膀胱癌细胞;然后,采用MTT实验检测细胞增殖,Transwell实验检测细胞侵袭,流式细胞仪检测细胞凋亡,双荧光报告酶检测mi R-345的靶基因;最后,采用Western blot检测TGM1在细胞中的表达。结果:mi R-345在T24和RT4细胞中表达低于正常细胞(P0.05)。mi R-345过表达时,T24和RT4细胞的增殖侵袭能力减弱,细胞凋亡率上升;mi R-345表达沉默时,细胞增殖和侵袭能力增强,细胞凋亡率下降。双荧光报告基因检测结果显示TGM1为mi R-345的靶基因,mi R-345过表达抑制TGM1的表达(P0.05);mi R-345表达沉默时则表达上调(P0.05)。当TGM1表达沉默时,T24和RT4细胞的增殖和侵袭能力减弱,细胞凋亡率上升;TGM1过表达时该细胞的增殖和侵袭能力增强,细胞凋亡率下降。结论:mi R-345通过下调靶基因TGM1的表达,抑制膀胱癌细胞的增殖、侵袭并促进细胞凋亡。     

miR-10a对类风湿性关节炎滑膜细胞侵袭、迁移能力的影响及机制

目的:以类风湿性关节炎(RA)患者滑膜细胞为研究对象,明确mi R-10a对滑膜细胞侵袭、迁移能力的影响及机制。方法:首先用q RT-PCR对筛选得到的异常表达mi RNA进行验证,进而利用生物信息学分析结合报告基因、Western印迹方法,明确mi R-10a的靶基因,最后采用Transwell、划痕实验考察mi R-10a对RA成纤维细胞样滑膜细胞(FLS细胞)侵袭能力的影响。结果:mi R-10a在RA患者滑膜组织及细胞中低表达;TAK1和BTRC是mi R-10a的靶基因;mi R-10a可促进IL-6、IL-8等炎症因子的表达;mi R-10a可促进FLS细胞的侵袭、迁移。结论:mi R-10a可通过调节NF-κB的活性影响RA FLS细胞的侵袭、迁移。     

唇腭裂患儿下调表达的miRNA相关研究

目的:唇腭裂是口腔颌面部最常见的先天性畸形,危害严重。mi RNA在细胞分化,生物发育及疾病发生发展过程中发挥巨大作用,越来越多的受到科研人员的关注。本课题对唇腭裂患儿下调表达的mi RNA与唇腭裂相关性进行验证研究,为mi RNA应用在唇腭裂防治中奠定一定的基础。方法:通过芯片分析方法检测唇腭裂患儿表达下调的mi RNA,利用MIRDB、TARGETSCAN-VERT和RNA22-HSA这三个生物信息学软件对唇腭裂患儿表达下调的mi RNA进行靶基因预测分析,验证候选mi RNA与唇腭裂具有相关性。结果:得出唇腭裂患儿中出现差异表达下调的mi RNA有hsa-mi R-3119,hsa-mi R-3915等73个,其中hsa-mi R-3611对应的靶基因GABRB3和hsa-mi R-764对应的靶基因F13A1有文献报道与唇腭裂具有相关性。结论:hsa-mi R-3611,hsa-mi R-764可能与唇腭裂的发生存在关联。     

miR-335在肿瘤组织中的表达及其预测靶基因的生物信息学分析

目的:分析miR-335在多种肿瘤组织与癌旁组织中的表达,预测其靶基因并进行相关生物信息学分析,为进一步研究miR-335在肿瘤中的调控机制提供理论基础。方法:分析miR-335的保守性及在多个肿瘤组织中的表达;预测miR-335靶基因,并使用DAIVID对miR-335靶基因进行生物信息学分析。结果:miR-335序列高度保守,在肝癌、肺癌、乳腺癌、肝内胆管癌、脂肪肉瘤中表达下调(P<0.05)。预测miR-335靶基因共34个,靶基因集合功能富集于细胞迁移、凋亡、转录调控,以及蛋白质分子连接、细胞骨架组成等生物学过程和分子功能(P<0.05);主要参与了轴突向导和黏着斑信号通路、黑素瘤疾病信号通路及TGF-β信号通路(P<0.05)。结论:miR-335在多种肿瘤中表达异常,且涉及多个生物学过程和信号转导通路,与肿瘤的发生发展密切相关。     

过表达miR-455抑制宫颈癌细胞SiHa的生长

研究表明,microRNA(miRNA)可作为癌基因或抑癌基因发挥功能、调控细胞增殖和凋亡等生物学行为,与肿瘤的发生发展密切相关. 在本研究中,我们检测了miR- 455在宫颈癌组织中的表达变化及其对宫颈癌SiHa细胞生物学功能的影响. Real- time PCR实验结果显示,miR-455在宫颈癌组织样本中较正常宫颈组织表达明显降低. 瞬时转染miR-455 mimics使其在SiHa细胞中过表达. CCK-8及流式细胞术分析显示, 过表达miR-455明显抑制细胞增殖,促进细胞凋亡,导致细胞G1/S期阻滞. Real- time PCR分析显示,PI3KR1,BCL2L2 mRNA明显降低.上述研究结果表明, miR-455可显著降低SiHa细胞存活能力,是一个潜在的抑癌基因.     

miR-335 orchestrates cell proliferation, migration and differentiation in human mesenchymal stem cells

In spite of the extensive potential of human mesenchymal stem cells (hMSCs) in cell therapy, little is known about the molecular mechanisms that regulate their therapeutic properties. We aimed to identify microRNAs (miRNAs) involved in controlling the transition between the resting and reparative phenotypes of hMSCs, hypothesizing that these miRNAs must be present in the undifferentiated cells and downregulated to allow initiation of distinct activation/differentiation programs. Differential miRNA expression analyses revealed that miR-335 is significantly downregulated upon hMSC differentiation. In addition, hMSCs derived from a variety of tissues express miR-335 at a higher level than human skin fibroblasts, and overexpression of miR-335 in hMSCs inhibited their proliferation and migration, as well as their osteogenic and adipogenic potential. Expression of miR-335 in hMSCs was upregulated by the canonical Wnt signaling pathway, a positive regulator of MSC self-renewal, and downregulated by interferon-γ (IFN-γ), a pro-inflammatory cytokine that has an important role in activating the immunomodulatory properties of hMSCs. Differential gene expression analyses, in combination with computational searches, defined a cluster of 62 putative target genes for miR-335 in hMSCs. Western blot and 3'UTR reporter assays confirmed RUNX2 as a direct target of miR-335 in hMSCs. These results strongly suggest that miR-335 downregulation is critical for the acquisition of reparative MSC phenotypes.     

miR-204 functions as a tumor suppressor by regulating SIX1 in NSCLC

The involvement of miR-204 in lung cancer development is unclear. In our study, we analyzed the expression of miR-204 in tumor- and adjacent-tissue samples from 141 patients with non-small cell lung cancer (NSCLC). MiR-204 expression was decreased in tumor samples compared with non-cancerous tissue-derived controls. Moreover, miR-204 expression negatively correlated with homeobox protein SIX1 expression, tumor size and metastasis. MiR-204 silencing in miR-204-positive NSCLC cell lines promoted cell invasion and proliferation. Concomitantly, MiR-204 overexpression resulted in reduced cell proliferation and invasion, upregulated E-cadherin and downregulated N-cadherin and Vimentin expression. SIX1 was identified as a potential target of miR-204, and SIX1 silencing partially compromised the invasive and proliferative capacity of miR-204-deficient cells. Thus, miR-204 may be involved in the NSCLC development.     

Downregulation of lysyl oxidase-like 4 LOXL4 by miR-135a-5p promotes lung cancer progression in vitro and in vivo

Aberrant microRNAs are widely identified in multiple cancers, including lung cancer. miR-135a-5p can function as a significant tumor regulator in diverse cancers via impacting multiple genes in oncogenic pathways. Nevertheless, the biological role of miR-135a-5p in lung cancer is poorly known. Here, we investigated its function in lung cancer. As exhibited, miR-135a-5p was elevated in lung cancer cells in contrast to BEAS-2B cells. Then, we inhibited miR-135a-5p expression by transfecting LV-anti-miR-135a-5p into lung cancer cells. As displayed, miR-135a-5p was obviously reduced in A549 and H1299 cells. Knockdown of miR-135a-5p repressed lung cancer cell growth and cell proliferation. Meanwhile, cell colony formation capacity was depressed, cell apoptosis was enhanced and cell cycle progression was blocked in G1 phase by inhibition of miR-135a-5p in vitro. Additionally, the migration and invasion of A549 and H1299 cells was strongly depressed by LV-anti-miR-135a-5p. For another, by using informatics analysis, lysyl oxidase-like 4 (LOXL4) was speculated as the downstream target of miR-135a-5p. We validated their direct correlation and moreover, overexpression of miR-135a-5p restrained LOXL4 levels in lung cancer cells. Subsequently, we proved that miR-135a-5p promoted lung cancer development via targeting LOXL4 by carrying out the in vivo assays. Taken these together, our study revealed miR-135a-5p might be indicated as a perspective for lung cancer via targeting LOXL4.     

Global identification of miR-373-regulated genes in breast cancer by quantitative proteomics

Although microRNAs (miRNAs) have been reported to play an important role in carcinogenesis, their molecular mechanism remains largely unknown because of our limited understanding of miRNA target genes. miR-373 was found to be capable of promoting breast cancer invasion and metastasis, but only a target gene was experimentally identified on the basis of mRNA expression analysis. In this study, we used SILAC-based quantitative proteomics to globally identify the genes regulated by miR-373. Totally, 3666 proteins were identified, and 335 proteins were found to be regulated by miR-373. Among the 192 proteins that were downregulated by miR-373, 27 (14.1%) were predicted to have at least one potential match site at their 3'-UTR for miR-373 seed sequence. However, miR-373 did not affect the mRNA level of the five selected candidate targets, TXNIP, TRPS1, RABEP1, GRHL2 and HIP1, suggesting that the protein expressions were regulated by miR-373 via translational inhibition instead of mRNA degradation. Luciferase and mutation assays validated that TXNIP and RABEP1 were the direct target genes of miR-373. More than 30 proteins reported to be involved in cancer invasion and metastasis were found to be regulated by miR-373 in breast cancer for the first time.     

Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells

Advanced prostate cancers are known to acquire not only invasive capabilities but also significant resistance to chemotherapy-induced apoptosis. To understand how microRNAs (miRNAs) may contribute to prostate cancer resistance to apoptosis, we compared microRNA expression profiles of a benign prostate cancer cell line WPE1-NA22 and a highly malignant WPE1-NB26 cell line (derived from a common lineage). We found that miR-205 and miR-31 are significantly downregulated in WPE1-NB26 cells, as well as in other cell lines representing advanced-stage prostate cancers. Antiapoptotic genes BCL2L2 (encoding Bcl-w) and E2F6 are identified as the targets of miR-205 and miR-31, respectively. By downregulating Bcl-w and E2F6, miR-205 and miR-31 promote chemotherapeutic agents-induced apoptosis in prostate cancer cells. The promoter region of the miR-205 gene was cloned and was found to be hypermethylated in cell lines derived from advanced prostate cancers, contributing to the downregulation of the gene. Treatment with DNA methylation inhibitor 5-aza-2′-deoxycytidine induced miR-205 expression, downregulated Bcl-w, and sensitized prostate cancer cells to chemotherapy-induced apoptosis. Thus, downregulation of miR-205 and miR-31 has an important role in apoptosis resistance in advanced prostate cancer.     

Downregulation of miR-33b promotes non-small cell lung cancer cell growth through reprogramming glucose metabolism miR-33b regulates non-small cell lung cancer cell growth

Glucose metabolism is a common target for cancer regulation and microRNAs (miRNAs) are important regulators of this process. Here we aim to investigate a tumor-suppressing miRNA, miR-33b, in regulating the glucose metabolism of non-small cell lung cancer (NSCLC). In our study, quantitative real-time polymerase chain reaction (qRT-PCR) showed that miR-33b was downregulated in NSCLC tissues and cell lines, which was correlated with increased cell proliferation and colony formation. Overexpression of miR-33b through miR-33b mimics transfection suppressed NSCLC proliferation, colony formation, and induced cell-cycle arrest and apoptosis. Meanwhile, miR-33b overexpression inhibited glucose metabolism in NSCLC cells. Luciferase reporter assay confirmed that miR-33b directly binds to the 3′-untranslated region of lactate dehydrogenase A (LDHA). qRT-PCR and Western blot analysis showed that miR-33b downregulated the expression of LDHA. Moreover, introducing LDHA mRNA into cells over-expressing miR-33b attenuated the inhibitory effect of miR-33b on the growth and glucose metabolism in NSCLC cells. Taken together, these results confirm that miR-33b is an anti-oncogenic miRNA, which inhibits NSCLC cell growth by targeting LDHA through reprogramming glucose metabolism.